#1 Clinical Trials Search in Europe

Buprenorphine

This article explores the use of buprenorphine in clinical trials for treating opioid use disorder (OUD). Buprenorphine, a partial opioid agonist, has shown promise as an effective medication-assisted treatment option. Various formulations, including extended-release injections, are being studied to improve treatment adherence and outcomes for individuals struggling with opioid addiction. The trials examine safety, efficacy, pharmacokinetics, and long-term effects of different buprenorphine preparations in OUD patients.

Table of Contents

What is Buprenorphine?

Buprenorphine is a medication used primarily in the treatment of opioid use disorder (OUD), also known as opioid addiction[1]. It belongs to a class of drugs called opioid partial agonists, which means it activates opioid receptors in the brain, but to a lesser degree than full opioids like heroin or prescription painkillers[1].

Buprenorphine is known by several brand names and formulations, including:

  • Subutex (sublingual tablets)
  • Suboxone (combination of buprenorphine and naloxone)
  • Sublocade (extended-release injection)
  • CAM2038 (long-acting subcutaneous injection)

These different forms allow for flexibility in treatment approaches, catering to individual patient needs and preferences[2][3].

How Buprenorphine Works

Buprenorphine works by binding to the same receptors in the brain that are affected by opioids like heroin or prescription painkillers. However, it has some unique properties that make it effective for treating opioid addiction:

  1. Partial activation: Buprenorphine only partially activates opioid receptors, which helps reduce cravings and withdrawal symptoms without producing the full “high” associated with other opioids[1].
  2. Ceiling effect: There’s a limit to how much effect buprenorphine can have, even at higher doses. This reduces the risk of overdose and makes it safer than full opioid agonists[4].
  3. Long-lasting action: Buprenorphine has a long half-life, meaning it stays in the system for an extended period. This allows for less frequent dosing and helps maintain stable levels in the body[5].
  4. Blockade effect: At sufficient doses, buprenorphine can block the effects of other opioids, which can help prevent relapse if a person uses opioids while on buprenorphine[4].

Conditions Treated with Buprenorphine

Buprenorphine is primarily used to treat:

  • Opioid Use Disorder (OUD): This is the main condition for which buprenorphine is prescribed. It helps individuals manage withdrawal symptoms, reduce cravings, and maintain long-term recovery from opioid addiction[1].
  • Chronic Pain: In some cases, buprenorphine may be used to treat chronic pain, especially in individuals with a history of opioid use disorder[1].
  • Acute Pain: Research is ongoing to determine the effectiveness of buprenorphine in managing acute pain, particularly in individuals already taking buprenorphine for OUD[1].

Forms of Buprenorphine

Buprenorphine is available in several forms, each with its own advantages:

  • Sublingual tablets (Subutex): These are placed under the tongue to dissolve and are typically used in the early stages of treatment[5].
  • Buprenorphine/naloxone combination (Suboxone): This formulation includes naloxone to deter misuse and is often used for maintenance treatment[1].
  • Extended-release injection (Sublocade): This monthly injection provides a steady level of buprenorphine, reducing the need for daily dosing[2].
  • Long-acting subcutaneous injection (CAM2038): Available in weekly (q1w) and monthly (q4w) formulations, this provides flexible dosing options for patients[3].

Effectiveness of Buprenorphine

Research has shown that buprenorphine is effective in treating opioid use disorder. Some key findings include:

  • Reduction in illicit opioid use: Studies have shown that patients on buprenorphine have a higher percentage of negative urine drug screens for opioids[3].
  • Improved treatment retention: Patients on long-acting formulations like Sublocade or CAM2038 show good retention rates in treatment programs[3].
  • Reduced cravings and withdrawal symptoms: Buprenorphine effectively manages both the desire to use opioids and the physical symptoms of withdrawal[3].
  • Flexibility in treatment: The availability of different formulations allows for personalized treatment approaches[2][3].

Side Effects and Safety

While buprenorphine is generally considered safe and effective, it can cause side effects. Common side effects may include:

  • Nausea and vomiting
  • Constipation
  • Headache
  • Drowsiness
  • Sweating
  • Dry mouth

More serious side effects, though rare, can include liver problems, allergic reactions, and respiratory depression (slowed breathing). It’s important to discuss any side effects with your healthcare provider[5].

While buprenorphine has a lower risk of overdose compared to full opioid agonists, it’s still possible to misuse the medication. Therefore, it’s crucial to take it exactly as prescribed by your doctor[4].

Administration and Dosing

The administration of buprenorphine depends on the formulation:

  • Sublingual tablets: Placed under the tongue to dissolve, typically once daily[5].
  • Sublocade injection: Administered monthly by a healthcare professional as a subcutaneous injection[2].
  • CAM2038 injection: Can be given weekly or monthly as a subcutaneous injection by a healthcare provider[3].

Dosing is individualized based on the patient’s needs and response to treatment. It often starts with a lower dose and may be adjusted over time[5].

Monitoring During Treatment

During buprenorphine treatment, patients are typically monitored for:

  • Treatment effectiveness: This may include urine drug screens and self-reported opioid use[3].
  • Withdrawal symptoms: Using scales like the Clinical Opiate Withdrawal Scale (COWS) and Subjective Opiate Withdrawal Scale (SOWS)[3].
  • Cravings: Often assessed using Visual Analog Scales (VAS) for desire and need to use opioids[3].
  • Side effects and overall health: Regular check-ups to assess any adverse effects and overall well-being[5].

Ongoing Research

Research on buprenorphine is ongoing, with studies focusing on:

  • Long-term safety and effectiveness of extended-release formulations[3].
  • Use of buprenorphine in managing acute pain in patients with OUD[1].
  • Brain mechanisms involved in the response to buprenorphine treatment[6].
  • Rapid initiation protocols for extended-release buprenorphine[7].

These ongoing studies aim to improve treatment protocols and expand our understanding of how buprenorphine can best be used to help individuals with opioid use disorder.

Aspect Details
Study Types Open-label, randomized, pharmacokinetic, safety, and efficacy studies
Buprenorphine Formulations Extended-release injections (e.g., Sublocade, CAM2038), sublingual tablets
Duration Ranging from 12 weeks to 48 weeks
Key Outcomes Measured Safety, efficacy, pharmacokinetics, treatment retention, opioid use reduction
Assessment Tools Urine drug screens, COWS, SOWS, VAS for cravings, CGI scales
Patient Populations Adults with moderate to severe opioid use disorder
Dosing Strategies Weekly and monthly injections, dose adjustments based on individual needs
Safety Monitoring Adverse events, injection site reactions, withdrawal symptoms

FAQ

  • What is buprenorphine and how does it work for opioid use disorder? Buprenorphine is a partial opioid agonist medication used to treat opioid use disorder. It works by binding to the same receptors in the brain as other opioids, but with less intense effects. This helps reduce cravings and withdrawal symptoms while preventing the euphoric effects of other opioids.
  • What are the different formulations of buprenorphine being studied? Clinical trials are examining various formulations of buprenorphine, including sublingual tablets, extended-release subcutaneous injections (like Sublocade and CAM2038), and long-acting depot injections. These different forms aim to improve treatment adherence and provide longer-lasting effects.
  • How long do the clinical trials for buprenorphine typically last? The duration of clinical trials for buprenorphine varies. Some studies last for a few months, while others extend up to a year or more. For example, one long-term safety study examined the effects of weekly and monthly buprenorphine injections over a 48-week period.
  • What are some of the main outcomes measured in these clinical trials? Key outcomes measured in buprenorphine clinical trials include safety and tolerability, treatment retention, reduction in opioid use (measured through urine drug screens and self-reports), withdrawal symptoms, cravings, and pharmacokinetic parameters like plasma drug concentrations.
  • Are there any potential side effects or risks associated with buprenorphine treatment? While buprenorphine is generally considered safe and effective, clinical trials monitor for potential side effects. These may include injection site reactions, headache, nausea, and constipation. Researchers also assess for any serious adverse events or unexpected reactions throughout the treatment period.

Ongoing Clinical Trials on Buprenorphine

  • Study of daridorexant and buprenorphine combination treatment for patients with opioid use disorder

    Recruiting

    2 1 1
    Investigated drugs:
    Sweden

  • Comparing Buprenorphine/Naloxone and Methadone for Opioid Use Disorder in Patients with Chronic Pain: A Study on Reducing Opioid Misuse

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on Buprenorphine for Treating Severe Suicidal Thoughts in Patients with Major Depression

    Recruiting

    2 1 1
    Investigated drugs:
    France

  • Study on Opioid Detoxification Using Buprenorphine, Naloxone, and Oxycodone for Patients with Persistent Spinal Pain Syndrome Type II

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

  • Study on Long-Term Effects of Buprenorphine in Adults with Opioid Use Disorder

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Sweden

Glossary

  • Opioid Use Disorder (OUD): A chronic medical condition characterized by the problematic use of opioids leading to significant impairment or distress. It involves a pattern of opioid use that can result in health problems, disability, and failure to meet major responsibilities.
  • Buprenorphine: A partial opioid agonist medication used to treat opioid use disorder. It helps reduce cravings and withdrawal symptoms associated with opioid addiction while blocking the effects of other opioids.
  • Medication-Assisted Treatment (MAT): An approach to treating opioid use disorder that combines medications (such as buprenorphine) with counseling and behavioral therapies to provide a comprehensive treatment program.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion. In clinical trials, PK studies help determine appropriate dosing and administration methods.
  • Extended-Release: A formulation of a medication designed to release the active ingredient slowly over time, allowing for less frequent dosing and potentially improving treatment adherence.
  • Subcutaneous Injection: An injection given into the fatty tissue layer between the skin and muscle. This method is used for some extended-release formulations of buprenorphine.
  • Clinical Opiate Withdrawal Scale (COWS): A tool used by healthcare professionals to assess and measure the severity of opioid withdrawal symptoms in patients.
  • Subjective Opiate Withdrawal Scale (SOWS): A self-report questionnaire used to measure the intensity of opioid withdrawal symptoms experienced by patients.
  • Visual Analog Scale (VAS): A measurement tool used to assess subjective characteristics or attitudes that cannot be directly measured, such as pain intensity or drug cravings.
  • Treatment Retention: The extent to which patients remain engaged in a treatment program over time, which is an important measure of treatment success in addiction medicine.

References

  1. https://clinicaltrials.gov/study/NCT03266445
  2. https://clinicaltrials.gov/study/NCT03861338
  3. https://clinicaltrials.gov/study/NCT02672111
  4. https://clinicaltrials.gov/study/NCT02611752
  5. https://clinicaltrials.gov/study/NCT01738503
  6. https://clinicaltrials.gov/study/NCT04454411
  7. https://clinicaltrials.gov/study/NCT03993392